Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Qu...
April 18 2017 - 4:00PM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that it plans to report its financial results for its
fiscal second quarter ended March 31, 2017 after the U.S. markets
close on May 8, 2017. Enanta management will host a conference call
at 4:30 p.m. ET to discuss these results and provide an update on
Enanta’s research and development pipeline.
Conference Call and Webcast Information
To participate in the live conference call, please dial (855)
840-0595 in the U.S. or (518) 444-4814 for international callers. A
replay of the conference call will be available starting at
approximately 7:30 p.m. Eastern time on May 8, 2017, through 11:59
p.m. Eastern time on May 12, 2017 by dialing (855) 859-2056 from
the U.S. or (404) 537-3406 for international callers. The passcode
for both the live call and the replay is 6851190. A live audio
webcast of the call and replay can be accessed by visiting the
“Calendar of Events” section on the “Investors” page of Enanta’s
website at www.enanta.com.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs for viral infections and liver diseases. Enanta’s research
and development efforts are currently focused on the following
disease targets: non-alcoholic steatohepatitis (NASH)/ primary
biliary cholangitis (PBC), respiratory syncytial virus (RSV) and
hepatitis B virus (HBV).
Enanta has discovered novel protease inhibitors for use against
the hepatitis C virus (HCV). These protease inhibitors, developed
through Enanta’s collaboration with AbbVie, include paritaprevir,
part of AbbVie’s currently marketed HCV regimens, and glecaprevir
(ABT-493), Enanta’s second protease inhibitor product, which AbbVie
is developing as part of its investigational, pan-genotypic HCV
regimen of glecaprevir/pibrentasvir (G/P) now in registration in
the U.S., the E.U. and Japan. Royalties and any further milestone
payments from this collaboration will provide additional funding
for Enanta’s earlier development programs, including its Phase 1
FXR agonist program for NASH/PBC, and its preclinical programs for
HBV and RSV. Please visit www.enanta.com for more information on
Enanta’s programs and pipeline.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170418005999/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Sep 2023 to Sep 2024